Compare Stocks: ELAN, TEVA, ONC, and RPRX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ELAN Elanco Animal Health	$23.03 +2.3%	$24.56	$17.11 ▼ $27.98	$11.52B	1.67	5.71 million shs	645,929 shs
ONC BeOne Medicines	$344.65 -3.2%	$302.92	$253.95 ▼ $385.22	$37.90B	0.49	287,968 shs	65,036 shs
RPRX Royalty Pharma	$58.31 -0.4%	$56.76	$34.08 ▼ $60.44	$33.66B	0.43	3.53 million shs	203,228 shs
TEVA Teva Pharmaceutical Industries	$36.27 -0.7%	$33.47	$17.33 ▼ $37.39	$42.31B	0.86	7.17 million shs	364,853 shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ELAN Elanco Animal Health	+1.91%	-7.04%	-11.89%	+13.44%	+26.32%
ONC BeOne Medicines	-0.85%	+7.95%	+16.13%	+21.39%	+15.77%
RPRX Royalty Pharma	-1.11%	+2.27%	+5.19%	+10.80%	+60.61%
TEVA Teva Pharmaceutical Industries	-0.88%	+5.06%	+14.85%	+6.50%	+112.18%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ELAN Elanco Animal Health	$23.03 +2.3%	$24.56	$17.11 ▼ $27.98	$11.52B	1.67	5.71 million shs	645,929 shs
ONC BeOne Medicines	$344.65 -3.2%	$302.92	$253.95 ▼ $385.22	$37.90B	0.49	287,968 shs	65,036 shs
RPRX Royalty Pharma	$58.31 -0.4%	$56.76	$34.08 ▼ $60.44	$33.66B	0.43	3.53 million shs	203,228 shs
TEVA Teva Pharmaceutical Industries	$36.27 -0.7%	$33.47	$17.33 ▼ $37.39	$42.31B	0.86	7.17 million shs	364,853 shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ELAN Elanco Animal Health	+1.91%	-7.04%	-11.89%	+13.44%	+26.32%
ONC BeOne Medicines	-0.85%	+7.95%	+16.13%	+21.39%	+15.77%
RPRX Royalty Pharma	-1.11%	+2.27%	+5.19%	+10.80%	+60.61%
TEVA Teva Pharmaceutical Industries	-0.88%	+5.06%	+14.85%	+6.50%	+112.18%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ELAN Elanco Animal Health	2.77	Moderate Buy	$29.09	26.32% Upside
ONC BeOne Medicines	3.00	Buy	$402.14	16.68% Upside
RPRX Royalty Pharma	3.00	Buy	$60.86	4.36% Upside
TEVA Teva Pharmaceutical Industries	2.90	Moderate Buy	$42.22	16.41% Upside

Current Analyst Ratings Breakdown

Latest ELAN, TEVA, ONC, and RPRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2026	RPRX Royalty Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy (B-)
8/12/2026	TEVA Teva Pharmaceutical Industries	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$40.00 ➝ $42.00
8/10/2026	ONC BeOne Medicines	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$370.00
8/7/2026	ONC BeOne Medicines	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/7/2026	RPRX Royalty Pharma	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$58.00 ➝ $62.00
8/6/2026	ONC BeOne Medicines	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
8/6/2026	RPRX Royalty Pharma	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$66.00
8/6/2026	RPRX Royalty Pharma	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$65.00
8/6/2026	ONC BeOne Medicines	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
8/6/2026	ONC BeOne Medicines	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$403.00 ➝ $407.00
8/6/2026	ELAN Elanco Animal Health	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$31.00 ➝ $33.00

(Data available from 8/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ELAN Elanco Animal Health	$4.72B	2.44	$2.41 per share	9.54	$13.19 per share	1.75
ONC BeOne Medicines	$5.34B	7.08	$3.75 per share	91.86	$47.16 per share	7.31
RPRX Royalty Pharma	$2.38B	14.12	$4.70 per share	12.40	$16.99 per share	3.43
TEVA Teva Pharmaceutical Industries	$17.31B	2.44	$3.68 per share	9.85	$6.66 per share	5.45

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ELAN Elanco Animal Health	-$232M	-$0.41	N/A	18.28	1.33	-3.96%	8.13%	3.99%	N/A
ONC BeOne Medicines	$286.93M	$5.68	60.82	30.99	N/A	10.70%	14.23%	7.82%	N/A
RPRX Royalty Pharma	$770.95M	$1.45	40.31	10.54	1.38	32.14%	30.01%	14.91%	N/A
TEVA Teva Pharmaceutical Industries	$1.41B	$0.60	60.51	11.97	3.93	4.08%	32.64%	6.34%	N/A

Latest ELAN, TEVA, ONC, and RPRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2026	Q2 2026	ELAN Elanco Animal Health	$0.2692	$0.34	+$0.0708	$0.11	$1.31 billion	$1.37 billion
8/5/2026	Q2 2026	ONC BeOne Medicines	$1.40	$2.05	+$0.65	$2.05	$1.66 billion	$1.71 billion
8/5/2026	Q2 2026	RPRX Royalty Pharma	$1.27	$1.32	+$0.05	$0.04	$758.93 million	$674.14 million
7/29/2026	Q2 2026	TEVA Teva Pharmaceutical Industries	$0.08	$0.02	-$0.06	-$0.49	$4.02 billion	$4.14 billion
6/30/2026	Q2 2026	TEVA Teva Pharmaceutical Industries	N/A	$0.02	N/A	-$0.49	N/A	$4.14 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ELAN Elanco Animal Health	N/A	N/A	N/A	N/A	N/A
ONC BeOne Medicines	N/A	N/A	N/A	N/A	N/A
RPRX Royalty Pharma	$0.94	1.61%	+24.01%	64.83%	5 Years
TEVA Teva Pharmaceutical Industries	N/A	N/A	N/A	N/A	N/A

Latest ELAN, TEVA, ONC, and RPRX Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/17/2026	RPRX Royalty Pharma	quarterly	$0.2350	1.62%	8/14/2026	8/14/2026	9/10/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ELAN Elanco Animal Health	0.58	2.05	1.10
ONC BeOne Medicines	0.17	3.40	3.06
RPRX Royalty Pharma	0.88	2.80	2.80
TEVA Teva Pharmaceutical Industries	1.56	0.88	0.67

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ELAN Elanco Animal Health	97.48%
ONC BeOne Medicines	48.55%
RPRX Royalty Pharma	54.35%
TEVA Teva Pharmaceutical Industries	54.05%

Insider Ownership

Company	Insider Ownership
ELAN Elanco Animal Health	1.14%
ONC BeOne Medicines	6.19%
RPRX Royalty Pharma	18.84%
TEVA Teva Pharmaceutical Industries	0.54%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ELAN Elanco Animal Health	9,400	499.62 million	493.93 million	Optionable
ONC BeOne Medicines	12,000	109.72 million	102.93 million	N/A
RPRX Royalty Pharma	80	575.83 million	467.35 million	Optionable
TEVA Teva Pharmaceutical Industries	33,950	1.17 billion	1.16 billion	Optionable

ELAN, TEVA, ONC, and RPRX Headlines

Recent News About These Companies

Teva Pharmaceutical Industries (NYSE:TEVA) Stock Price Expected to Rise, Barclays Analyst Says

August 14 at 1:48 AM | americanbankingnews.com

Teva Pharmaceutical Industries (NYSE:TEVA) Sets New 1-Year High After Analyst Upgrade

August 13 at 10:39 AM | marketbeat.com

Humana agrees not to reference Teva's Israel ties at US drug trial

August 13 at 10:16 AM | reuters.com

Teva Pharmaceutical Industries Ltd: Moody's Ratings Upgrades Teva to Investment Grade, Reflecting the Ongoing Execution of Pivot to Growth Strategy

August 13 at 7:02 AM | finanznachrichten.de

ADAMA Appoints Orly Pascal as Chief Human Resources Officer

August 13 at 7:02 AM | finance.yahoo.com

AMRX Stock Surges 44.8% in 3 Months: Can the Rally Keep Running Now?

August 12 at 5:45 PM | finance.yahoo.com

Is AMRX Stock a Buy as Growth Improves but Execution Risks Persist?

August 12 at 5:45 PM | finance.yahoo.com

Can Amneal's Kashiv Deal Turn Biosimilars Into a Major Growth Engine?

August 12 at 5:45 PM | finance.yahoo.com

Teva Pharmaceutical Industries (NYSE:TEVA) Price Target Raised to $42.00

August 12 at 8:47 AM | marketbeat.com

Moody’s Ratings Upgrades Teva to Investment Grade, Reflecting the Ongoing Execution of Pivot to Growth Strategy

August 12 at 7:44 AM | theglobeandmail.com

Pacer Advisors Inc. Sells 484,736 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

August 12 at 4:55 AM | marketbeat.com

Moody’s Ratings Upgrades Teva to Investment Grade, Reflecting the Ongoing Execution of Pivot to Growth Strategy

August 11 at 12:58 PM | finance.yahoo.com

Teva Pharmaceutical Industries Ltd. Receives Moody’s Upgrade to Investment-Grade Baa3 Rating

August 11 at 8:31 AM | quiverquant.comQ

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Given Average Rating of "Moderate Buy" by Brokerages

August 11 at 4:28 AM | marketbeat.com

Empowered Funds LLC Increases Holdings in Teva Pharmaceutical Industries Ltd. $TEVA

August 9, 2026 | marketbeat.com

Assenagon Asset Management S.A. Grows Position in Teva Pharmaceutical Industries Ltd. $TEVA

August 8, 2026 | marketbeat.com

Teva (TEVA) Q2 2026 Earnings Call Transcript

August 7, 2026 | fool.com

SUPN vs. TEVA: Which Stock Should Value Investors Buy Now?

August 7, 2026 | finance.yahoo.com

SUPN vs. TEVA: Which Stock Should Value Investors Buy Now?

August 7, 2026 | zacks.com

Bank of America Corp DE Has $119.24 Million Stock Holdings in Teva Pharmaceutical Industries Ltd. $TEVA

August 7, 2026 | marketbeat.com

Arrowstreet Capital Limited Partnership Reduces Stock Holdings in Teva Pharmaceutical Industries Ltd. $TEVA

August 7, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ELAN, TEVA, ONC, and RPRX Company Descriptions

Elanco Animal Health NYSE:ELAN

$23.03 +0.52 (+2.31%)

As of 10:41 AM Eastern

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

BeOne Medicines NASDAQ:ONC

$344.65 -11.36 (-3.19%)

As of 10:41 AM Eastern

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Royalty Pharma NASDAQ:RPRX

$58.31 -0.25 (-0.42%)

As of 10:41 AM Eastern

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

Teva Pharmaceutical Industries NYSE:TEVA

$36.27 -0.25 (-0.68%)

As of 10:41 AM Eastern

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ELAN, TEVA, ONC, and RPRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ELAN, TEVA, ONC, and RPRX Earnings

Compare Dividends

Latest ELAN, TEVA, ONC, and RPRX Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ELAN, TEVA, ONC, and RPRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ELAN, TEVA, ONC, and RPRX Company Descriptions

Elanco Animal Health NYSE:ELAN

BeOne Medicines NASDAQ:ONC

Royalty Pharma NASDAQ:RPRX

Teva Pharmaceutical Industries NYSE:TEVA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools